ASX News
Investor Briefing – TheraPharm GmbH Acquisition
Melbourne (Australia) – 1st December 2020. Telix Pharmaceuticals Provides Investor Briefing: TheraPharm GmbH Acquisition
Targeted Radiation for Cell Therapies – TheraPharm GmbH Acquisition.
To view the presentation please click here.
The Investor Call and Q&A was recorded and is now available for on-demand public viewing here.
More Articles
ASX News
Launch of the International NOBLE Registry of Telix’s SPECT-Based Prostate Cancer Imaging Agent
Melbourne (Australia) and Brussels (Belgium) – 19 April 2021. Telix announces the launch of the international NOBLE Registry of Telix’s...
ASX News
Telix Pharmaceuticals Limited – Notice of Annual General Meeting 2021
Melbourne (Australia) – 12 April 2021. Telix Pharmaceuticals provides notice of The Annual General Meeting of Shareholders on Wednesday 12...
ASX News
Telix Pharmaceuticals and Grand River Aseptic Manufacturing Complete Agreement for Commercial Manufacturing of Illuccix®
Melbourne (Australia) and Indianapolis, IN (U.S.A.) – 31st March 2021. Telix announces it has completed an agreement with Grand River...
Corporate Spotlight
Telix Appoints Darren Patti, Chief Operating Officer, Telix Pharmaceuticals (US) Inc.
29th March 2021 – Corporate Spotlight | Darren Patti joins Telix as Chief Operating Officer, Telix Pharmaceuticals (US) Inc.
ASX News
Telix Pharmaceuticals and ITM Complete Global Agreements for Lutetium-177 Radioisotope Supply
Melbourne (Australia) and Garching (Germany) – 18th March 2021. Telix announces it has extended its non-exclusive global clinical and commercial supply...
Corporate Spotlight
Telix Appoints Sébastien Linard as General Manager, Telix European Manufacturing Facility
8th March 2021 – Corporate Spotlight | Sébastien Linard joins Telix as General Manager of Telix’s European Manufacturing in Seneffe,...
ASX News
Telix Pharmaceuticals and ITM Complete Global Agreements for Lutetium-177 Radioisotope Supply
Melbourne (Australia) and Garching (Germany) – 18th March 2021. Telix announces it has extended its non-exclusive global clinical and commercial...
ASX News
Telix Pharmaceuticals Releases Results for the Year Ended 31 December 2020 and 2020 Annual Report
Melbourne (Australia) – 26th February 2021. Telix Pharmaceuticals Limited Releases Full-Year 2020 Results and 2020 Annual Report.
ASX News
Telix and Kanazawa University Cleared to Commence Prostate Cancer Imaging Study in Japan
Melbourne (Australia) and Kyoto (Japan) – 22nd February 2021. Telix Japan receives Clinical Trial Notification (CTN) clearance to commence a...
ASX News
Telix FY2020 Results and Company Update Conference Call
Melbourne (Australia) – 16th February 2021. Telix to present the Company’s FY2020 results together with an update on Telix’s operations.
ASX News
Czech Republic Grants National Authorisation for the Use of Telix’s Prostate Cancer Imaging Product
Melbourne (Australia) and Liège (Belgium) – 16th February 2021. Telix announces the Ministry of Health of the Czech Republic is...
ASX News
Telix and Heidelberg University Hospital to Develop Next Generation Theranostics
Melbourne (Australia) and Heidelberg (Germany) – 10th February 2021. Telix announces research cooperation agreement with Heidelberg University Hospital to develop...
Corporate Spotlight
Industry Leaders’ Round-Table at SNMMI Mid-Winter Satellite Symposium
3rd February 2021 | Corporate Spotlight – Recording of Industry Leaders’ Round-Table Discussion at SNMMI Mid-Winter Symposium: Ga-68 PSMA-11: Advances...
ASX News
First U.S. Patients Dosed in Phase III ZIRCON Trial of Renal Cancer Imaging Product
Melbourne (Australia) and Indianapolis, IN (U.S.A.) – 25th January 2021. Telix Pharmaceuticals announces the first U.S. patients have been dosed...
Corporate Spotlight
Telix Pharmaceuticals Appoints Danielle Meyrick MD as CMO, Asia-Pacific
22nd January 2021 – Corporate Spotlight | Telix Pharmaceuticals welcomes Dr Danielle Meyrick as Chief Medical Officer, Asia Pacific
Corporate Spotlight
ARTMS and Telix Pharmaceuticals Announce Successful Production of 68Ga PSMA-11 with Cyclotron Produced 68Ga from a Solid Target
Burnaby, Canada and Indianapolis, USA, January 12, 2021 – ARTMS Inc. and Telix announce successful production of Telix’s prostate cancer...
ASX News
Telix Pharmaceuticals Files New Drug Submission with Health Canada for Prostate Cancer Imaging Product
Melbourne (Australia) and Indianapolis, IN (USA) – 16th December 2020. Telix has filed a New Drug Submission (NDS) with Health Canada...
ASX News
Telix Pharmaceuticals and Mauna Kea Technologies Launch Urologic Oncology Alliance
Melbourne (Australia) – 16th December 2020. [Article updated with new video 16th February 2021] Telix Pharmaceuticals announces collaboration with Mauna...
ASX News
Telix and Kanazawa University Commence Japanese Clinical Study for Prostate Cancer Imaging
Melbourne (Australia) – 14th December 2020. Telix announces its subsidiary, Telix Pharmaceuticals Japan KK, has entered a clinical study collaboration...
ASX News
Telix Completes IP Agreement with the University of Southampton (UK) Granting Exclusive Access to TRALA Clinical Trial Data
Melbourne (Australia) – 14th December 2020. Telix Pharmaceuticals Limited announces today that its wholly-owned subsidiary TheraPharm GmbH has completed an...
ASX News
Telix Granted TGA Priority Review for Prostate Cancer Imaging
Melbourne (Australia) – 7th December 2020. Telix has been granted Priority Review status for TLX591-CDx (68Ga-PSMA-11), a radiopharmaceutical for the...
ASX News
Telix and DuChemBio Announce Korean Partnership for Advanced Prostate Cancer Imaging
Melbourne (Australia) and Seoul (South Korea) – 3rd December 2020. Telix Pharmaceuticals announces it has entered into a licensing and partnership...
ASX News
Australian TGA Accepts Telix’s Prostate Cancer Imaging Product Submission and Commences Priority Evaluation Process
Melbourne (Australia) – 14 April 2021. Telix announces the Australian Therapeutic Goods Administration has accepted its prostate cancer imaging product submission and commenced...